Anthem Blue Cross and Blue Shield

Precertification Required for Hemophilia Drugs

Anthem Blue Cross and Blue Shield precertification requirements will change for certain hemophilia drugs. The 2015 Medicare Advantage list hemophilia drugs requiring precertification. As of July 1, 2015 providers must call for prior authorization of these drugs:

- C9136 Factor VIII, fc fusion protein, (recombinant)
- J7178 Human fibrinogen concentrate
- J7180 Factor XIII (antihemophilic factor, human)
- J7181 Factor XIII A-subunit, (recombinant), [Tretten]
- J7182 Factor VIII, (antihemophilic factor, recombinant), [Novoeight]
- J7183 Von Willebrand factor complex (human), Wilate
- J7185 Factor VIII (antihemophilic factor, recombinant) [Xyntha]
- J7186 Antihemophilic factor VIII/von Willebrand factor complex (human), per factor VIII IU [Alphanate]
- J7187 Von Willebrand factor complex [Humate-P]
- J7189 Factor VIIa (antihemophilic factor, recombinant)
- J7190 Factor VIII anti-hemophilic factor, human, [Hemofil M, Doate DVI, Monoclote-P]
- J7191 Factor VIII, antihemophilic factor [porcine]
- J7192 Factor VIII (antihemophilic factor, recombinant), [Advate, Helixate-FS, Kogenate-FS, Recombinate]
- J7193 Factor IX (antihemophilic factor, purified, non-recombinant) p [AlphaNine SD, Mononine]
- J7194 Factor IX complex, [Bebulin VH, Profilnine SD]
- J7195 Factor IX (antihemophilic factor, recombinant) ,[Benefix]
- J7198 Anti-inhibitor
- J7199 Hemophilia clotting factor, [Eloctate]
- J7200 Factor IX, (antihemophilic factor, recombinant), [Rixubis]
- J7201 Factor IX, Fc fusion protein (recombinant),